Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 701–800 of 876
Tailored management of advanced squamous non-small cell lung cancer (NSCLC)
Levra, M. G., & Novello, S. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-012-0034-9 · Cited by 1
BRCA1/2 Mutation Frequency is HIGH in Japanese Triple-Negative Breast Cancer Patients
Shigenaga, R., Akashi‐Tanaka, S., UCHIDA, S., Ikeda, M., OYAMA, H., Yoshida, R., Suzuki, K., Enokido, K., Sawada, T., Yotsumoto, J., et al. (2014) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.26.219 · Cited by 1
Smith, K. L., & Isaacs, C. J. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0049-1 · Cited by 1
Potential for targeted therapy in prostate cancers with ERG abnormalities
Williamson, S. R., & Cheng, L. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2011.100 · Cited by 1
Fujita, T., Mizukami, T., Okawara, T., Inoue, K., & Fujimori, M. (2013) · Breast Cancer · doi:10.1007/s12282-013-0452-8 · Cited by 1
Two cases of spindle cell carcinoma of the breast – Usefulness of immunohistochemical analysis
Okubo, S., Kurebayashi, J., Sonoo, H., Yamashita, T., Kanomata, N., & Moriya, T. (2012) · Institutional Repositories DataBase (IRDB) · Cited by 1
Tsukuda, G., Date, Y., Asonuma, K., Wada, Y., Isozaki, M., Inagaki, T., OMATU, M., Kunimura, T., Nakamura, S., Kushima, M., et al. (2013) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.25.83 · Cited by 1
TRIPLE NEGATIVE BREAST CANCER IN ELDERLY PATIENTS CLINICAL APPROACH
Ficherasalvatore, & Catania, V. E. (2014) · Cited by 1
Drug treatment for triple-negative metastatic breast cancer
Smirnova, O. V., Borisov, V. I., & Velsher, L. Z. (2015) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20154674-82 · Cited by 1
Jeschke, U., Mumm, J., Kölbl, A. C., & Andergassen, U. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s101677 · Cited by 1
Current treatment options for metastatic breast cancer: what now?
Rugo, H. S., O’Shaughnessy, J., & Perez, E. A. (2011) · PubMed · Cited by 1
Self-citationPARP inhibitors: the story is still unfolding.
Tripathy, D. (2011) · PubMed · Cited by 1
Gado, N. M. A., Ibrahim, D. R. D., Atef, D., & Kanaan, A. (2016) · International Journal of Cancer Therapy and Oncology · doi:10.14319/ijcto.42.6 · Cited by 1
Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer
Barton, S. R., & Turner, N. C. (2011) · CRC Press eBooks · doi:10.3109/9781841848129-7 · Cited by 1
Triple-Negative and Basal-like Carcinoma
Lacroix‐Triki, M., Geyer, F. C., Weigelt, B., & Reis-Filho, J. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0604-8.00024-2 · Cited by 1
Berry, S. M., Carlin, B. P., Lee, J. J., & Muller, P. (2010) · CRC Press eBooks · doi:10.1201/ebk1439825488-6 · Cited by 1
What is the future in the treatment of triple-negative breast cancer?
Nayır, E., & Köşeci, T. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.08.001 · Cited by 1
Targeting Genome Instability and DNA Repair
Locatelli, M., & Curigliano, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_68 · Cited by 1
Curigliano, G. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_31 · Cited by 1
Salinas-Meza, A., Arias, B. S., Quesada, A., Fernández, S. V., & Román, J. J. M. (2018) · Revista Médica de la Universidad de Costa Rica · doi:10.15517/rmucr.v12i2.36232 · Cited by 1
Nomura, S., Shinozaki, T., & Hamada, C. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1695625 · Cited by 1
Hernández, A. L. (2011) · Cited by 1
Genetic Susceptibility to Triple‐Negative Breast Cancers
Wong‐Brown, M. W., & Scott, R. J. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0025352 · Cited by 1
Eucker, J. (2013) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-12117 · Cited by 1
Ingoldsby, H. (2011) · Arrow@dit (Dublin Institute of Technology) · doi:10.13025/16139 · Cited by 1
EpCAM and CSPG4 scFv based fusion proteins for the treatment of triple negative breast cancer
Amoury, M., Fischer, R., Barth, S., & Kiessling, F. M. (2018) · RWTH Publications (RWTH Aachen) · Cited by 1
Radwan, E. M. (2015) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia) · Cited by 1
Sheng, X., Dai, H., Song, Y., & Ma, X. (2021) · Research Square · doi:10.21203/rs.3.rs-1106099/v1 · Cited by 1
Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer
Edelman, M. J., & Ijaz, N. (2011) · Medical radiology · doi:10.1007/174_2011_312 · Cited by 1
Phua, Y. W. (2013) · UNSWorks (UNSW Sydney) · doi:10.26190/unsworks/16850 · Cited by 1
Genetic profile of DNA repair genes in Triple Negative Breast Cancer
Spugnesi, L. (2015) · Electronic Theses and Dissertations Repository (University of Pisa) · Cited by 1
Vennin, C. (2016) · theses.fr (ABES) · doi:10.70675/e6d6d601zcc34z449dzb06ez631c07dba08e · Cited by 1
Rôle des déterminants génétiques constitutionnels dans le cancer du sein
Curtit, E. (2017) · theses.fr (ABES) · doi:10.70675/8daa3e5fz8315z427cz8450zdfeb505b2b30 · Cited by 1
Radovich, M. (2012) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1947 · Cited by 1
Design, Development, and Evaluation of Tools to Study Cellular ADP-ribose Polymer Metabolism
Steffen, J. D. (2011) · UA Campus Repository (The University of Arizona)
Triple negative breast cancer: Breast cancer research in evolution
Eng‐Wong, J., Hunsberger, S., & Zujewski, J. A. (2011) · Breast Disease · doi:10.3233/bd-2010-0314
Targeted Molecular Therapy for Patients with Ovarian Cancer
Farghaly, S. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8271-0_12
Operator Training Simulators for Geothermal Power Plants
Romero, G., Luis, A., Antonio, J., & Avalos-Valenzuela, H. (2009) · InTech eBooks · doi:10.5772/7402
Bioinformatic Identification of Genomic Alterations in Breast Cancer
Edgren, H. (2012) · Helda - University of Helsinki Institutional Repository
Acquired tamoxifen resistance and promotion of angiogenic responses in breast cancer
Hayes, E. (2012) · ORCA Online Research @Cardiff (Cardiff University)
The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review
Liontos, M., Karageorgopoulou, S., Michalaki, V., Contis, J., Bournakis, E., Vassiliou, J. G., Dimopoulos, M. A., & PAPADIMITRIOU, C. A. (2015) · Journal of Solid Tumors · doi:10.5430/jst.v5n2p18
Dynamic Wnt gene expression in the oncogenesis of breast cancer in Tianjin albino 2 strain mice
Liu, F., Sun, B., Zhang, D., Wang, J., Dong, X., Gu, Q., & Zhao, X. (2013) · Clinical Oncology and Cancer Research · doi:10.3969/j.issn.1000-8179.2013.07.001
Sikov, W. M. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0092-6
What Are the Most Important New Targets in Breast Cancer?
Cianfrocca, M. E. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0068-y
PARP inhibition: opening up new horizons?
Heitz, F., & du Bois, A. (2011) · Clinical Investigation · doi:10.4155/cli.11.51
Treatment of Metastatic Triple-Negative Breast Cancer
Glendenning, J., Irshad, S., & Tutt, A. N. J. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0062-4
Management of women with BRCA1 / 2 mutation-associated breast cancer
Bayraktar, S., & Glück, S. (2012) · Breast Cancer Management · doi:10.2217/bmt.12.22
Biologisch stratifizierte Therapie
Sicking, I., & Schmidt, M. (2014) · Im Focus Onkologie · doi:10.1007/s15015-014-0011-y
The Role of PARP Inhibitors in Breast Cancer
Gelmon, K. A. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.050
PARP inhibitors: pitfalls and promises
Anderson, R. A. (2013)
Molecular diagnostics in pancreatic cancer
Chang, D. K.-F., Grimmond, S. M., & Biankin, A. V. (2011) · doi:10.2217/ebo.11.330
Current Status and Future Direction of PARP Inhibition in Cancer Therapy
Rafii, S., Kaye, S. B., & Banerjee, S. N. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch33
Phase I–II Targeted Treatments
Pezaro, C. J., Omlin, A. G., & Bono, J. S. D. (2014) · Current clinical urology · doi:10.1007/978-1-4939-1176-9_13
Suppression of mammary tumorigenesis by a Gemini vitamin D analog and a synthetic truterpenoid
So, J. Y. (2013) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3jw8ck7
Roles of the ING1 Epigenetic Regulator in Breast Cancer
Thakur, S. S. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27691
BRCA- und weitere Suszeptibilitäts-Gene
Leinert, E., de Gregorio, N., & Schwentner, L. (2015) · Info Onkologie · doi:10.1007/s15004-015-0977-4
Won, J. (2015) · cIRcle (University of British Columbia) · doi:10.14288/1.0167714
On replicating studies, phase II and phase III trials, and other vagaries of clinical research
Streiner, D. L., & Norman, G. R. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70063-3
BRCA Gene Testing and Clinicopathological Study of Familial Breast Cancer
Nomizu, T., Matsuzaki, M., Katagata, N., Sakuma, T., Kanke, Y., Ito, T., NIHEI, M., & Yamaguchi, Y. (2014) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.75.1765
Inhibition of DNA repair as a therapeutic strategy
Schwartzberg, L. S. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70083-9
B.BHUPAL, & Satyanarayana, S. (2014) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.33084
Response to neoadjuvant chemotherapy and survival in patients with triple-negative breast cancer
Ohtani, S., Kochi, M., Itoh, M., Takata, S., Matsuura, H., & Higaki, K. (2011) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.72.2995
Breast cancer and molecular targeted drugs
Doihara, H. (2013) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.125.243
Belcon, M. C. (2015) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc000206
Timing Is Everything: Brca2 and p53 Mutations in Pancreatic Cancer
Fearon, E. R. (2011)
Triple-negative breast cancer: not entirely negative.
Leone, J. P., & Puhalla, S. (2013) · PubMed
McLellan, J. L. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0072371
Expression and significance of PARP1 and PAR in triple-negative breast cancer
李慧兰, 翟丽丽, Zhai, L., & Fu, L. (2014) · Clinical Oncology and Cancer Research · doi:10.3969/j.issn.1000-8179.20141138
The maze of PARP inhibitors in ovarian cancer.
Nair, A., & Chen, A. P. (2012) · PubMed
De, P. K., Carlson, J. H., Leyland-Jones, B. R., & Dey, N. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_3 · Cited by 1
BRCA Mutation and PARP Inhibitors
Weil, M. K., Kummar, S., Doroshow, J. H., & Chen, A. P. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b15029-16
(2013) · CRC Press eBooks · doi:10.1201/b14587-17
Dialysis Catheters and Recombinant Tissue Plasminogen Activator
Ruohola, A., & Tähtinen, P. A. (2011)
Omics‐Based Nanopharmacy: Powerful Tools Toward Precision Medicine
Rosenblum, D., & Peer, D. (2016) · Wiley eBooks · doi:10.1002/9783527800681.ch5
Kurreck, A. (2016) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-11051
Molecular Basis of PARP Inhibition and Future Opportunities in Ovarian Cancer Therapy
Collins, B. L., Gonzalez, A. N., Hanbury, A., Ceppi, L., & Penson, R. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00007-0
“Meeting after ASCO 2011”, 1–2 July 2011, Gdańsk
Duchnowska, R. (2011) · Oncology in Clinical Practice
Mapping Genetic Interaction Networks in Yeast
Baryshnikova, A. (2013) · TSpace (University of Toronto)
Targeting Defective DNA Repair Pathways in Triple-Negative Breast Cancer
Gradishar, W. J. (2011) · Journal watch · doi:10.1056/oh201101250000002
Shea, L. D. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada559941
Fatty acid synthase expression and inhibition in triple-negative breast cancer
Giró‐Perafita, A. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Cyclin E1 as a therapeutic target in high grade serous ovarian cancer
Au‐Yeung, G. (2017) · Minerva Access (University of Melbourne)
Inzidenz und Outcome von BRCA1-Mutationsträgerinnen im tripel-negativen Kollektiv
Klan, S. (2015) · mediaTUM (Technical University of Munich)
Investigation into mechanisms of metastasis in breast cancer and pancreatic cancer
Moore, G. (2017) · Arrow@dit (Dublin Institute of Technology)
Developing three dimensional models of breast cancer
Leeper, A. D. (2014) · ERA
Poly(ADP-ribose) polymerase inhibitors and epithelial ovarian cancer
McNally, T. P., Lai, G. G., & Penson, R. T. (2012) · doi:10.2217/ebo.11.116
Fejerman, L., & Ziv, E. (2011) · doi:10.2217/ebo.11.26
Systemic Treatment of HER2-Negative Metastatic Breast Cancer
Bayraktar, S., & Aydıner, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96947-3_22
ANDROGEN RECEPTOR POSITIVITY IN TRIPLE-NEGATIVE BREAST CANCER
M, M. P. J., Kalaichelvi, K., & Kumar, S. (2018) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2018/885
Novel Approaches to Studying BRCA Variants of Unknown Clinical Significance
Cochran, R. L. (2014)
Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy
Bayraktar, S., & Aydıner, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16792-9_31
Timmermans, L. (2019) · Ghent University Academic Bibliography (Ghent University)
Interação entre células tronco de membrana amniótica e tumor mamário canino in vitro
Borghesi, J. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2019.tde-09092019-103106
Physical, technical and tactical performance analysis of the chinese football super league
Gai, Y. (2019) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.55643
Billaud, A. (2020) · theses.fr (ABES) · doi:10.70675/2e9e8fb9z32d6z43d2z9534zb1ac5dc9176a
A SCREEN FOR PEPTIDES TARGETING CHEMORESISTANT METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Subramanian, S. (2020) · Digital Commons-TMC (Texas Medical Center)
Genes de Predisposición al Cáncer de Mama
Orozco‐Hernández, J. P., Marín‐Medina, D. S., Martínez-Muñoz, M. A., & Martínez, J. W. (2018) · Memorias
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.